Harmony Biosciences (HRMY)

• Market cap: $2.24B
• 1 day: 1.45%
• 5 days: 0%
• 1 month: -3.77%
• 3 months: 7.63%
• 6 months: 23.56%
• Year to date: 3%
• 1 year: 29.89%
• 5 years: -6.3%
• 10 years: 4.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Employees: 293